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Abstract 
Chronic kidney disease (CKD) is a major cause of death and morbidity in Australia and worldwide. DNA 
vaccination has been used for targeting foreign antigens to induce immune responses and prevent 
autoimmune disease, viral infection and cancer. However, the use of DNA vaccination has been restricted 
by a limited ability to induce strong immune responses, especially against self-antigens which are limited 
by mechanisms of self-tolerance. Furthermore, there have been few studies on the potential of DNA 
vaccination in chronic inflammatory diseases, including CKD. We have established strategies of DNA 
vaccination targeting specific self-antigens in the immune system including co-stimulatory pathways, T 
cell receptors and chemokine molecules, which have been effective in protecting against the development 
of CKD in a variety of animal models. In particular, we find that the efficacy of DNA vaccination is 
improved by dendritic cell (DC) targeting and can protect against animal models of autoimmune nephritis 
mimicking human membranous nephropathy. In this review, we summarize several approaches that have 
been tested to improve the efficacy of DNA vaccination in CKD models, including enhanced DNA vaccine 
delivery methods, DNA vaccine modifications and new molecular targets for DNA vaccination. Finally, we 
discuss the specific application of DNA vaccination for preventing and treating CKD. 
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Abstract: Chronic kidney disease (CKD) is a major cause of death and morbidity in Australia and worldwide. DNA 
vaccination has been used for targeting foreign antigens to induce immune responses and prevent autoimmune 
disease, viral infection and cancer. However, the use of DNA vaccination has been restricted by a limited ability to in-
duce strong immune responses, especially against self-antigens which are limited by mechanisms of self-tolerance. 
Furthermore, there have been few studies on the potential of DNA vaccination in chronic inflammatory diseases, 
including CKD. We have established strategies of DNA vaccination targeting specific self-antigens in the immune 
system including co-stimulatory pathways, T cell receptors and chemokine molecules, which have been effective in 
protecting against the development of CKD in a variety of animal models. In particular, we find that the efficacy of 
DNA vaccination is improved by dendritic cell (DC) targeting and can protect against animal models of autoimmune 
nephritis mimicking human membranous nephropathy. In this review, we summarize several approaches that have 
been tested to improve the efficacy of DNA vaccination in CKD models, including enhanced DNA vaccine delivery 
methods, DNA vaccine modifications and new molecular targets for DNA vaccination. Finally, we discuss the specific 
application of DNA vaccination for preventing and treating CKD. 
Keywords: DNA vaccination, dendritic cell, DEC205, CD40, cytokine, costimulatory molecular, active Heymann 
nephritis (HN), adriamycin nephropathy (AN)
Introduction
Chronic kidney disease (CKD) is characterized 
by the progressive loss of renal function and 
structural injury leading eventually to end stage 
kidney disease (ESKD) [1, 2]. Currently, treat-
ment strategies that successfully delay pro-
gression from CKD to ESKD are limited and 
patients with ESKD require costly dialysis or 
renal transplantation. Therefore, new strate-
gies to manage CKD are important from both a 
clinical and public health perspective. DNA vac-
cination delivers plasmid DNA encoding the tar-
get gene to induce both humoral and cellular 
immune responses. This strategy has been 
used for more than two decades to treat auto-
immune disease, viral infection and cancer 
[3-7]. While DNA vaccines have reached clinical 
use, in general they have been limited by their 
restricted ability to induce strong immune 
responses [8] and this is a particular problem in 
generating responses to self-antigens where 
there is intrinsic self-tolerance [3, 9]. In addi-
tion, the potential of DNA vaccination as thera-
peutic approach for CKD has not been assessed 
fully. Our previous studies have shown that DNA 
vaccination targeting T cell receptor (TCR) sub-
sets in Heymann nephritis (HN) [10], or target-
ing the chemokine CCL2 (monocyte chemoat-
tractant protein 1) in Adriamycin nephropathy 
(AN) are protective and induce specific cellular 
and antibody responses against the target anti-
gen [11, 12]. A number of strategies have been 
utilized to enhance efficacy. We have recently 
tested a plasmid containing the gene encoding 
a single-chain Fv antibody specific for the den-
dritic cell-restricted antigen-uptake receptor 
DEC205 developed by the Steinman laboratory. 
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By cloning a gene of interest, co-stimulatory 
molecule CD40, into this plasmid, we have 
demonstrated that this particular vaccine 
(DEC205-CD40) can prevent the development 
of HN, a rat model of human membranous 
nephropathy (KI 2012). More broadly DC tar-
geted vaccines against other chemokine tar-
gets such as CX3CR1 induce functional anti-
body responses against self-antigens [13].
We have called this induction of immune 
responses against targeted self antigens “dae-
dalic in reference to the Greek myth of Daedalus 
who induced self-injury while flying to close to 
the sun.
Similar to standard vaccines, DNA vaccines are 
believed to confer protection through neutraliz-
ing antibodies. Our previous studies suggest 
that DNA vaccination results in antigen-specific 
antibody responses that can be measured by 
enzyme-linked immunosorbent assays, as well 
as assays that measure functional antibody 
activity. We have found that enhanced antigen 
specific T cell responses using the the tetanus 
toxoid element p30 in our plasmid enhances 
antigen specific T cell responses as measured 
by ELISPOT and provide additional T cell help 
for antibody production [12]. 
Improvement of efficacy of DNA vaccine by 
modification of vaccine and delivery methods 
There are several ways of delivering a plasmid 
DNA into target cells. One of the most common-
ly used delivery methods is intramuscular injec-
tion. However, intramuscular injection is often 
not enough to elicit a strong immune response 
in rodents. Various approaches have therefore 
been adopted to improve the immunogenicity 
of DNA vaccines such as the prime-boost immu-
nization of protein antigen in adjuvant and the 
use of modified DNA delivery systems including 
electroporation [14-16]. Our previous studies 
have shown that the administration of antigens 
(recombinant proteins or peptides) in Complete 
Freund’s Adjuvant (CFA) after injection of plas-
mid DNA encoding the target antigen enhance 
the immunogenicity of the vaccine in mice. CFA 
is composed of dried or inactivated mycobacte-
rial components and itself is an immunopoten-
tiator of cell-mediated immunity and produc-
tion of antibodies by stimulating TNF-α 
production by APCs [17]. We have also demon-
strated that fusion of the gene encoding the 
tetanus toxoid T helper epitope P30 with target 
genes is able to increase the immunogenicity of 
DNA vaccines by engaging T cell help [12].
Electroporation is another useful delivery 
approach which enhances the efficacy of DNA 
vaccines by facilitating plasmid entry into tar-
get cells [18]. Delivery of short pulses to the 
injection site causes temporary permeabiliza-
tion of the cell membrane, thereby facilitating 
DNA uptake. An increased antigen expression 
in mice, guinea pigs and rabbits has been 
observed previously with the use of electropor-
ation [18, 19]. Studies have suggested that 
applying an electric field to tissues in vivo sig-
nificantly increase DNA uptake and gene 
expression [7, 18]. We and others have also 
found that electroporation substantially 
increases DNA delivery and DNA vaccine poten-
cy in animal models of CKD.
Enhancement of DNA vaccination by targeting 
the encoded protein to dendritic cells (DCs)
One of the most promising methods for enhanc-
ing the efficacy of DNA vaccination is the selec-
tive targeting of DNA vaccine encoded antigens 
to the immune cells, especially antigen pre-
senting cells (APCs). This is due to the require-
ment for MHC Class I and II expression [20] and 
the expression of co-stimulatory molecules, 
particularly CD80 and CD86 which are impor-
tant for the efficient antigen processing, pre-
sentation and induction of T cell immune 
responses. DCs have been identified as the 
most potent APCs that can prime T cells in vivo 
[21]. DC targeting can be achieved by the use of 
DEC205 ScFv antibody constructs in the plas-
mid. These encode a fusion protein comprised 
of the vaccine antigen and a single-chain Fv 
antibody (scFv) specific for the DC-restricted 
antigen-uptake receptor DEC205. DEC205 tar-
geted DNA vaccines substantially increase anti-
body production and cellular responses [20, 
22]. As showed in Figure 1, antigen encoding 
sequence is incorporated into a DC-targeted 
DNA plasmid which contains scFv sequence 
encoding for an antibody directed at DEC205, 
then the plasmid DNA is delivered intramuscu-
larly with electroporation and taken up by DCs. 
DCs migrate into lymph nodes where they dif-
ferentiate and induce T cell and B cell respons-
es. Finally, antibody production and cellular 
response is induced by DC-targeted DNA 
vaccination. 
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DCs generate specific adaptive immunity 
against the vaccinated antigens or antigenic 
epitopes by augmenting T-cell mediated 
responses. After uptake of antigens, DCs 
migrate to secondary lymphoid organs where 
they process and present the antigens to naive 
T cells via MHC-I or II molecules inducing acti-
vation of antigen-specific T cells [23]. Antigen-
specific T cells include CD4+ T cells and CD8+ 
T cells. of CD4+ T cell subsets including the 
newly described T follicular helper cells secrete 
cytokines including IL-4 and IL-21 that induces 
B cell differentiation and lead to the production 
of protective neutralizing antibodies and forma-
tion of plasma and memory B cells [24]. Both 
CD4+ and CD8+ T cells can undergo further dif-
ferentiation and become memory cells [25].
There has been a relatively simplistic model of 
Th1 and Th2 differentiation driving different 
immune responses generated by DNA vaccines 
[26]. It has been postulated that, IL-12 or IL-4 
Figure 1. Immunological mechanisms of DNA vaccination in preventing Heymann Nephritis. Antigen encoding se-
quence is incorporated into a DC-targeted DNA plasmid which contains a scFv sequence encoding for antibodies 
directed against DEC205. Plasmid DNAs are delivered intramuscularly with electroporation and taken up by DCs. 
DCs migrate into lymph nodes where they differentiate and induce T cell and B cell responses. B cells differentiate 
into plasma cells and produce antigen-specific neutralizing antibodies limiting immune activation in chronic kidney 
disease. 
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can drive Th1 or Th2 cell development respec-
tively [27, 28]. Th2 responses further activate B 
cells to become antibody-secreting plasma 
cells leading to humoral responses [29] and 
that the type of T helper response induced is 
related to the method of DNA vaccine delivery, 
target sites and nature of immunogens. For 
example, needle injection (IM or ID) can induce 
a Th1 response while the gene gun method 
induces Th2 responses [30, 31]. Our results 
are different from this and we have found 
increased immunogenicity and antibody levels 
associated with IFN-γ secretion and Th1 forma-
tion with the addition of adjuvants such as P30. 
This may reflect the need for some form of 
inflammation to break self-tolerance [11-13].
In standard DNA vaccination against patho-
gens an important advantage of DNA vaccina-
tion is its capability of raising CTL (CD8+ effec-
tor cytotoxic T-lymphocyte) responses. CTL 
responses are activated by differentiated DCs 
through the MHC-I priming pathway and further 
augmented by CD4+ T helper cells [29]. DNA 
vaccines that target the MHC-I restricted path-
way via direct or cross priming of antigens 
greatly enhanced CTL responses in animal 
models [32, 33]. This was further emphasized 
recently with the development of a DNA vaccine 
encoding antigen peptide combined with an 
retention signal which targeted intercellular 
trafficking of MHC-I molecule presentation and 
produced significant CTL responses in mice 
with marked production of IFN-γ [34]. 
Furthermore, several studies had revealed that 
DNA vaccines against infectious agents such 
as HBV, influenza, and HIV strongly promote the 
CD8+ responses [23, 35, 36]. This differs from 
our studies against self antigens where the 
major aim is to induce blocking antibody 
responses.
Augmentation of immunity by DC-targeting DNA 
vaccination strategy has been tested in a num-
ber of disease models. It was previously shown 
that both a protective CD4+ T helper response 
and a CD8+ functional response were generat-
ed after vaccination of a recombinant gag virus 
vaccine against HIV in a mouse model with 
DC-targeting [37, 38]. More recent studies 
focused on the utilization of specific viral vec-
tors to suppress cancers and preventing the 
development of HIV in mouse models. Animals 
that received DC-targeted vaccine composed 
of modified adenoviral vectors generated sig-
nificantly more CD8+ cells (including CD62L-/
CD127+ effector memory cells), produced high-
er levels of IL-2 and were protected from mela-
noma tumor growth [39]. In another study, DNA 
vaccination using DC-targeted recombinant 
Newcastle disease virus (rNDV) vectors induced 
significant interferon production and generated 
HIV-gag antigen specific humoral and CD4+/
CD8+ T cell responses in mice [40]. Finally pri-
mate studies have demonstrated a 10-fold 
increase of immunogenicity in rhesus 
macaques after immunization with DNA vac-
cines encoding simian immunodeficiency virus 
antigen targeted to dendritic cells [41].
Autoimmune kidney disease targeted by DNA 
vaccination
Chronic kidney disease in humans and in 
mouse models involves both the cognate and 
innate immune systems and can be targeted at 
the levels of activation, differentiation and traf-
ficking. We have shown that blockade of CD40L 
improves renal outcomes in models of progres-
sive kidney disease [10, 54]. Strategies target-
ing either specific effector cells or the mode by 
which they are recruited to sites of inflamma-
tion may allow highly specific interventions that 
are long lasting, robust and do not have signifi-
cant side effects. 
Because of the clinical problems with CD40L as 
a clinical target due to thrombosis induced 
through CD40L on platelets we have focused 
on its ligand CD40. Many of the co-stimulatory 
pathways contain key molecules for therapeu-
tic intervention including some such as belata-
cept which blocks CD28 activation, which have 
reached clinical use. CD40 is expressed by B 
cells as well as other APCs and its ligand CD154 
which is expressed widely on T cells is a critical 
co-stimulatory pathway for T cell activation and 
the differentiation as well as class switching of 
B cells [42]. Blockade of CD40-CD154 is pro-
tective in a number of renal disease models 
such as rodent membranous glomerulonephri-
tis, chronic proteinuric renal disease and 
Adriamycin nephropathy (AN) [43-45]. Recent 
studies have demonstrated that CD40 and 
CD154 neutralizing antibodies are highly effec-
tive in blocking this pathway by generating anti-
gen specific Tregs and limiting antigen specific 
CD8 expansion [46], and their use has reached 
the stage of preclinical testing. Recent work by 
Steinman and others has shown the benefits of 
DNA vaccination for treatment of CKD
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targeting DNA encoded immunogens to DCs in 
situ using scFv antibodies directed at DEC205 
on the DC surface [22]. We have utilized this 
approach in targeting CD40 to DCs. The incor-
poration of a DC targeting element into a DNA 
vaccine allows the selective expression/uptake 
of vaccine encoded antigen by DC, which is 
critical for increased efficacy of MHC class II 
antigen presentation inducing an immune 
response to CD40 generating blocking antibod-
ies that protect against membranous 
glomerulonephritis.
Chemokine and chemokine receptors: CCL2, 
CX3CR1
Recently there has been an increased interest 
and progress in research on DNA vaccination 
targeting small immune biomolecules including 
T cell receptors CRs, cytokines and chemo-
kines in chronic inflammatory diseases. 
Chemokines (chemotactic cytokine) are a fami-
ly of small molecules that play an important 
role in inducing chemotaxis and coordinating 
leukocyte trafficking during an inflammatory 
response [47]. Fractalkine (CX3CL1), CCL2 
(Monocyte chemoattractant protein 1, MCP-1) 
and their receptors CX3CR1 and CCR2 are two 
important chemokine/receptor pairs which 
have been identified as contributing significant-
ly to monocyte recruitment. Their involvement 
in clinical diseases such as atherosclerosis, 
nephropathy, rheumatoid arthritis, allograft 
rejection and various types of cancer is widely 
evident [48-53]. Previous studies from our lab-
oratories and collaborators have demonstrated 
that DNA vaccination against TCR subsets in 
Heymann nephritis, and against the chemokine 
CCL2 in Adriamycin nephropathy is protective 
and induce specific cellular and antibody 
responses against the target antigen [10-12]. 
We have recently demonstrated that a 
DC-targeted DNA vaccine against CX3CR1 and 
CCL2 successfully induces humoral and cellu-
lar responses in mice. In this model, the gener-
ated autoantibodies restrict the motility of mac-
rophages towards activated endothelial cells 
shown by in vitro functional analysis [13]. These 
findings suggest a potential therapeutic role of 
chemokine/receptor DNA vaccination in pre-
venting inflammatory diseases. Studies of DNA 
vaccination for CKD models are summarized in 
Table 1.
Therapeutic applications for human renal 
diseases
Clinical application of DNA vaccines has 
occurred in viral infection, cancer and autoim-
mune diseases in recent years. The success of 
DNA vaccines against multiple strains of influ-
enza, human papillomavirus and HIV-1 in both 
preclinical models and clinical trials is promis-
ing [8]. However, potency and safety of DNA 
vaccines remain the major challenges to their 
application and had the major limitations in 
clinical applications. The ability to deliver vac-
cines better though gene guns and direct them 
to DCs allows more specific therapy without the 
need to increase adjuvants are major advanc-
es. While potency is a requirement for human 
studies, there are also concerns regarding the 
use of adjuvants in chronic inflammatory condi-
tions and of inducing potentially lifelong block-
ade of specific pathways in the immune system. 
However the results in animal studies are 
Table 1. DNA vaccination studies in kidney disease
Vaccine 
Target
Vaccine delivery 
method
Modification Disease Model Immunogenicity Prevention of  
Disease
TCRs bupivacaine pretreatment 
intramuscular injection 
challenged with Fx1A
Heymann nephritis  
(HN) in rats
production of autoantibody reduced proteinuria
reduced macrophage, T 
cells infiltration
reduced IFN- γ production
CCL2 bupivacaine pretreatment 
intramuscular injection 
P30 tetanus toxoid 
helper epitope 
sequence
Adriamycin Nephropa-
thy (AN) in rats
production of Anti-CCL2 Ab 
increased IFN-γ producing 
T cells
reduced glomerular and 
tubular damage
protected renal function 
reduced glomerular
and interstitial macrophage 
Infiltration
CD40 bupivacaine pretreatment 
intramuscular injection 
electroporation
challenged with Fx1A
P30 tetanus toxoid 
helper epitope 
sequence
DC-targeting
Adriamycin Nephropa-
thy (AN) in rats
production of anti-CD40 protected renal functions 
reduced renal structural 
injury
reduced macrophage, T 
cells infiltration and IgG 
deposition
DNA vaccination for treatment of CKD
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encouraging that specifically targeting self anti-
gens through DNA vaccination (Daedelic vacci-
nation) can be made potent enough to deliver 
clinical benefits. What remains to be tested is 
whether these beneifts can be extended to 
human.
Conclusions
The new approaches described to improve DNA 
vaccination induce more potent cellular and 
humoral response and present a potential pre-
ventative and therapeutic strategy for a variety 
of autoimmune diseases. Co-stimulatory mole-
cules and chemokines are important therapeu-
tic targets for DNA vaccination to treat CKD. 
Modulation of DNA vaccination with adjuvant 
and DC targeting improves efficacy without 
increasing toxicity during the treatment for 
CKD. Further studies are rquired to explore 
combining DNA vaccination approaches with 
enhanced methods for delivery, modified adju-
vants and new molecular gene targets. The 
induction of self-immune responses to block 
key pathways reflects many natural mecha-
nisms of self-regulation and may offer potent 
therapeutic strategies for the treatment of 
CKD. 
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